17:36 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

Solanezumab: Ph III discontinued

Lilly terminated the double-blind, placebo-controlled, international Phase III EXPEDITION-PRO trial of IV solanezumab every 4 weeks for up to 2 years to treat prodromal AD after reviewing data from the double-blind, international Phase III EXPEDITION3...
03:37 , Dec 17, 2016 |  BioCentury  |  Product Development

Not dead yet

The amyloid hypothesis may not be dead, but positive Phase Ib data for Biogen Inc. ’s aducanumab notwithstanding, the preponderance of evidence still suggests that attacking plaques is unlikely to be an effective intervention for...
08:00 , Jan 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Presenilin 1 (PSEN1; PS1)

Neurology INDICATION: Alzheimer's disease (AD) In vitro and rat studies suggest spirocyclic sulfone-based inhibitors of PSEN1-containing γ-secretase could help treat AD without the side effects of inhibiting γ-secretase containing PSEN1 and PSEN2 . Chemical synthesis...
07:00 , Apr 2, 2015 |  BC Innovations  |  Targets & Mechanisms

Presenilin U-turn

New data that turn the presenilin/γ-secretase hypothesis of Alzheimer's disease on its head do more than clear up the inconsistencies around the target that have confused the field for the last few years. As well...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Harvard Medical School other research news

Harvard scientists published in Cell the subcellular localization of presenilin-1 (PS-1) and presenilin-2 (PS-2), transmembrane proteins involved in progression of AD. The data suggest a role for PS-1 and PS-2 in chromosome organization and segregation...
07:00 , Oct 21, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) g-Secretase; presenilin 2 (PSEN2; PS2) A human genetic study suggests that g-secretase modulators for AD could elicit undesirable dermatological side effects. Linkage...
07:00 , May 3, 2010 |  BioCentury  |  Product Development

Pushing on with Pixuvri

Cell Therapeutics Inc. has raised more than $1 billion since its inception in 1992, including almost $350 million in the two years since the company stopped a Phase III trial of Pixuvri pixantrone because of...
07:00 , Oct 5, 2009 |  BioCentury  |  Finance

3Q Approvals/3Q Setbacks

3Q Approvals/3Q Setbacks Company Approval Allos Therapeutics Inc. (NASDAQ:ALTH) FDA grants accelerated approval of Folotyn pralatrexate to treat relapsed or refractory peripheral T cell lymphoma (PTCL) Anika Therapeutics Inc. (NASDAQ:ANIK) Canada approves Monovisc to treat...
07:00 , Sep 28, 2009 |  BC Week In Review  |  Clinical News

Opaxio paclitaxel poliglumex regulatory update

Cell Therapeutics withdrew an MAA for Opaxio paclitaxel poliglumex for first-line treatment of advanced non-small cell lung cancer (NSCLC) in poor performance status (PS2) patients. The company said it made the decision after EMEA's CHMP...
07:00 , Sep 28, 2009 |  BioCentury  |  Finance

Ebb & Flow

The pair of life sciences companies on IPO road shows may give investors and other companies clues on the opening of an IPO window. Profitable plasma-derived protein company Talecris Biotherapeutics Inc. may price this week,...